ArticleFrontiers in oncology2026
Clinical characteristics, management, and outcomes of lacrimal gland adenoid cystic carcinoma: a single-center series with contextual comparison to SEER data.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lacrimal gland adenoid cystic carcinoma (LGACC) is a rare, aggressive malignancy with limited epidemiological data, particularly from East Asian populations. Methods: This retrospective single-center series describes the clinicopathological features, treatment patterns, and outcomes of six consecutive patients with pathologically confirmed LGACC treated at the Cancer Hospital, Chinese Academy of Medical Sciences between 2012 and 2024. Findings were placed in the context of 22 cases extracted from the SEER database (ICD-O-3 histology code 8200/3, primary site C69.6). Survival was estimated for the institutional cohort and, descriptively, for a combined regional-stage cohort. Results: The median age at diagnosis was 31 years (range 26-59), with equal sex distribution. All tumors were regional-stage, and 66.7% were T3-4. All patients underwent surgery (orbital exenteration in 66.7%, globe-sparing resection in 33.3%; R0 margins in 33.3%) followed by high-dose conformal radiotherapy (66-70 Gy). One disease-related death occurred. Five-year overall survival (OS) and disease-specific survival (DSS) were both 75% (95% CI 42.6-100%). Local recurrence was observed in 16.7% and distant metastases in 50%. Treatment-related toxicity was mostly grade I-II. In a combined regional-stage cohort of 17 patients, surgery plus radiotherapy was associated with numerically higher 5-year OS (64.8% versus 26.7%) and DSS (74.1% versus 26.7%) compared with surgery or radiotherapy alone; these estimates are presented only for descriptive context and are limited by small numbers and wide confidence intervals. A sensitivity analysis excluding two SEER patients with unknown surgery status who received radiotherapy alone yielded consistent numerical trends. Chemotherapy was not used as primary or adjuvant therapy for the initial disease; it was given concurrently with radiotherapy for early postoperative residual disease in one patient and after delayed local recurrence in another. Discussion: In this series of predominantly advanced LGACC, surgery followed by adjuvant high-dose conformal radiotherapy achieved favorable local control with predominantly mild toxicity. Combined SEER comparisons should be interpreted cautiously because of the small sample size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.